PURPOSE: Incidental radiation dose to the heart and lung during breast radiation therapy (RT) has been associated with an increased risk of cardiopulmonary morbidity. We conducted a prospective trial to determine if RT with the Active Breathing Coordinator (ABC) can reduce the mean heart dose (MHD) by ≥20% and dose to the lung. METHODS AND MATERIALS: Patients with stages 0-III left breast cancer (LBC) were enrolled and underwent simulation with both free breathing (FB) and ABC for comparison of dosimetry. ABC was used during the patient's RT course if the MHD was reduced by ≥5%. The median prescription dose was 50.4 Gy plus a boost in 77 patients (90%). The primary endpoint was the magnitude of MHD reduction when comparing ABC to FB. Secondary endpoints included dose reduction to the heart and lung, procedural success rate, and adverse events. RESULTS: A total of 112 patients with LBC were enrolled from 2002 to 2011 and 86 eligible patients underwent both FB and ABC simulation. Ultimately, 81 patients received RT using ABC, corresponding to 72% procedural success. The primary endpoint was achieved as use of ABC reduced MHD by 20% or greater in 88% of patients (P < .0001). The median values for absolute and relative reduction in MHD were 1.7 Gy and 62%, respectively. RT with ABC provided a statistically significant dose reduction to the left lung. After a median follow up of 81 months, 8-year estimates of locoregional relapse, disease-free, and overall survival were 7%, 90%, and 96%, respectively. CONCLUSIONS: ABC was well tolerated and significantly reduced MHD while preserving local control. Use of the ABC device during RT should be considered to reduce the risk of ischemic heart disease in populations at risk.
PURPOSE: Incidental radiation dose to the heart and lung during breast radiation therapy (RT) has been associated with an increased risk of cardiopulmonary morbidity. We conducted a prospective trial to determine if RT with the Active Breathing Coordinator (ABC) can reduce the mean heart dose (MHD) by ≥20% and dose to the lung. METHODS AND MATERIALS: Patients with stages 0-III left breast cancer (LBC) were enrolled and underwent simulation with both free breathing (FB) and ABC for comparison of dosimetry. ABC was used during the patient's RT course if the MHD was reduced by ≥5%. The median prescription dose was 50.4 Gy plus a boost in 77 patients (90%). The primary endpoint was the magnitude of MHD reduction when comparing ABC to FB. Secondary endpoints included dose reduction to the heart and lung, procedural success rate, and adverse events. RESULTS: A total of 112 patients with LBC were enrolled from 2002 to 2011 and 86 eligible patients underwent both FB and ABC simulation. Ultimately, 81 patients received RT using ABC, corresponding to 72% procedural success. The primary endpoint was achieved as use of ABC reduced MHD by 20% or greater in 88% of patients (P < .0001). The median values for absolute and relative reduction in MHD were 1.7 Gy and 62%, respectively. RT with ABC provided a statistically significant dose reduction to the left lung. After a median follow up of 81 months, 8-year estimates of locoregional relapse, disease-free, and overall survival were 7%, 90%, and 96%, respectively. CONCLUSIONS: ABC was well tolerated and significantly reduced MHD while preserving local control. Use of the ABC device during RT should be considered to reduce the risk of ischemic heart disease in populations at risk.
Authors: Wei Wang; Thomas G Purdie; Mohammad Rahman; Andrea Marshall; Fei-Fei Liu; Anthony Fyles Journal: Int J Radiat Oncol Biol Phys Date: 2010-11-17 Impact factor: 7.038
Authors: Giovanna Gagliardi; Louis S Constine; Vitali Moiseenko; Candace Correa; Lori J Pierce; Aaron M Allen; Lawrence B Marks Journal: Int J Radiat Oncol Biol Phys Date: 2010-03-01 Impact factor: 7.038
Authors: Stine S Korreman; Anders N Pedersen; Lasse Rye Aarup; Trine J Nøttrup; Lena Specht; Håkan Nyström Journal: Int J Radiat Oncol Biol Phys Date: 2006-06-05 Impact factor: 7.038
Authors: Alyson McIntosh; Asal N Shoushtari; Stanley H Benedict; Paul W Read; Krishni Wijesooriya Journal: Int J Radiat Oncol Biol Phys Date: 2011-04-29 Impact factor: 7.038
Authors: Benjamin D Smith; I-Wen Pan; Ya-Chen T Shih; Grace L Smith; Jay R Harris; Rinaa Punglia; Lori J Pierce; Reshma Jagsi; James A Hayman; Sharon H Giordano; Thomas A Buchholz Journal: J Natl Cancer Inst Date: 2011-04-27 Impact factor: 13.506
Authors: Judith Hsia; Rebecca J Rodabough; Joann E Manson; Simin Liu; Matthew S Freiberg; William Graettinger; Milagros C Rosal; Barb Cochrane; Donald Lloyd-Jones; Jennifer G Robinson; Barbara V Howard Journal: Circ Cardiovasc Qual Outcomes Date: 2010-02-16
Authors: Sarah C Darby; David J Cutter; Marjan Boerma; Louis S Constine; Luis F Fajardo; Kazunori Kodama; Kiyohiko Mabuchi; Lawrence B Marks; Fred A Mettler; Lori J Pierce; Klaus R Trott; Edward T H Yeh; Roy E Shore Journal: Int J Radiat Oncol Biol Phys Date: 2010-03-01 Impact factor: 7.038
Authors: S Darby; P McGale; C Correa; C Taylor; R Arriagada; M Clarke; D Cutter; C Davies; M Ewertz; J Godwin; R Gray; L Pierce; T Whelan; Y Wang; R Peto Journal: Lancet Date: 2011-10-19 Impact factor: 79.321
Authors: V Salvestrini; G C Iorio; P Borghetti; F De Felice; C Greco; V Nardone; A Fiorentino; F Gregucci; I Desideri Journal: J Cancer Res Clin Oncol Date: 2021-12-01 Impact factor: 4.553
Authors: Hae Jin Park; Kwang-Ho Cheong; Taeryool Koo; Me Yeon Lee; Kyoung Ju Kim; Soah Park; Taejin Han; Sei-Kwon Kang; Boram Ha; Jai-Woong Yoon; Me Young Kim; Hoonsik Bae Journal: In Vivo Date: 2022 Jul-Aug Impact factor: 2.406
Authors: Lucas C Mendez; Alexander V Louie; Carolina Moreno; Matt Wronski; Andrew Warner; Eric Leung; Roberto Sakuraba; Juliana K Helito; Ana Rezende; Icaro T Carvalho; Eduardo Weltman Journal: Radiat Oncol Date: 2018-07-04 Impact factor: 3.481
Authors: Brigid E Hickey; Melissa L James; Margot Lehman; Phil N Hider; Mark Jeffery; Daniel P Francis; Adrienne M See Journal: Cochrane Database Syst Rev Date: 2016-07-18